Skinvisible signs licensing agreement for two acne products

May 17, 0008

Las Vegas - Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.

Las Vegas

- Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.

The two prescription anti-acne products are formulated with Invisicare,a patented polymer delivery technology, with the active ingredients Clindamycin HCL and Retinoic Acid.